A consecutive series of 570 patients with middle gastric cancer were evaluated in order to assess their prognosis, focusing on the relationship among the extent of gastric resection, consequent duodenal passage reconstruction, and postoperative adjuvant therapy.
Introduction
Since the first gastric resection performed by Theodor Billroth in 1881, several different surgical techniques have been developed, and much discussion has arisen over the treatment of choice for middle gastric cancer; namely, what is the suitable extent of resection (distal, proximal, or total gastrectomy). However, many controlled studies have failed to confirm the theoretical advantage of retaining the minimal amount of the stomach (Espat and Karpeh 1998) . The end points of many studies were operation time, intra-and postoperative complications, patient body weight, functional assessment, and quality of life. To our knowledge, from the viewpoint of long-term survival in carcinoma of the middle stomach, previous reports have failed to determine the best method of surgical therapy. This study analyzed the experience of a single institution in the treatment of carcinoma of the middle stomach with the aim of assessing the best principal method of surgical therapy and its long-term outcome, and supposing that patients receiving partial or subtotal (distal or proximal) gastrectomy (DG or PG, respectively) with DFP reconstruction might show better survival rates than those who received total gastrectomy (TG) without DFP reconstruction. 
Surgical techniques
In proximal gastrectomy, the stomach was transected 1.0cm orally from the fundic ring to the line that connected 1.0 to 2.0cm distal from the pyloric ring in the lesser curvature, and 10cm distal from the pyloric ring, thereby preserving two or three marginal branches of the right gastroepiploic artery and vein in the greater curvature.
These operations include a resection of the lesser and greater omentum. The amount of remaining stomach is almost similar in distal and proximal gastrectomies.
Extent of lymph node dissection
In PG with D2, lymph nodes along the right gastroepiploic artery and infrapyloric lymph nodes (No. 4d and 6) were removed skeletally, preserving two or three branches of the right gastroepiploic artery and vein. Co. Ltd., Tokyo, Japan) at 300mg/day, were administered orally from day 14 after surgery. In the immunotherapy group, PSK (Krestin; Kureha Chemical Industry Co. Ltd., and Tokyo, Japan) was administered orally at a dose of 3.0g/day from day 14 after gastrectomy. The nonspecific immunomodulator PSK is prepared from Coriolus vesicolor (Fr.) Quel, one of the Basidiomycetes. In Japanese clinical trials of PSK therapy in patients with gastric cancer, this agent was effective when combined with chemotherapy (Nakazato, Koike et al., 1994 , Ogoshi, Satou et al., 1995 .
Statistical analysis
Mean values were compared by Student's t-test. The chi-square test was used to compare the prevalence of characteristics. Results were considered significant when the P value (2-tailed) was less than 0.05. Survival curves were calculated using the KaplanMeier product-limit estimate, and differences in survival were assessed by the log-rank , and extent of gastric resection (subtotal (distal or proximal) vs. total gastrectomy) were evaluated to assess which prognostic independent factors were significant (significance level was set at .05), and 95%
confidence intervals (CI) were calculated.
All statistical analyses were carried out using SPSS 10.0 software (SPSS Inc., Chicago, USA).
Results

Patient characteristics
Characteristics of the 570 gastric cancer patients are listed in Table I 
Multivariate analysis
This multivariate analysis revealed that the strongest independent prognostic variable is residual tumor, and that age at operation, extent of gastric resection, duodenal food passage, depth of tumor, and lymph node metastasis were stronger significant independent prognostic factors in cases of 516 patients. The relative risk for these variables was 3.510, 2.196, 1.716, 1.655, 1.510, and 1.454, respectively (Table III) .
In patients who underwent only gastrectomy, the extent of gastric resection and the duodenal food passage were independent prognostic variables, whereas in those who underwent gastrectomy with postoperative adjuvant therapy, extent of gastric resection and duodenal food passage were not significant prognostic factors (Table III) . procedures for lesions of the middle stomach, and the clinical importance of a TG is also probably related to the more complete staging afforded by the lymphadenectomy, rather than to provision of a survival advantage. Shiu, Papacristou et al., (1980) failed to demonstrate that patients who underwent total gastrectomy showed better survival rates than those receiving subtotal gastrectomy in all TNM stages, though they did find that those who underwent total gastrectomy showed better survival rates than those who underwent subtotal gastrectomy in early-stage tumors (T1-4 N0 M0 and T1-4 N1 M0).
Several prospective controlled trials also failed to demonstrate that the extent of gastric resection was a significant predictor of long-term survival (Gouzi, Huguier et al., 1988; Haugstvedt, Viste et al., 1993; Bozzetti, Marubini et al., 1999) . However, several retrospective studies demonstrated that DG offered a significantly better survival rate than TG (Gennari, Bozzetti et al., 1986; Robertson, Chung et al., 1994) . On the other hand, a significantly better quality of life has been reported in patients who underwent DG in comparison with that of those who underwent subtotal gastrectomy (Davies, Johnston et al., 1998; Jentschura, Winkler, et al., 1997) .
On the other hand, although gastro-duodenal anastomosis (Billroth I) after DG is in general regarded by many surgeons as more physiologic than gastro-jejunal anastomosis (Billroth II), diversion of the duodenal content via a Roux-en-Y end-to-side anastomosis is considered to be the standard procedure after TG, especially in Western countries. Chareton, Landen et al., (1996) and Fuchs, Thiede et al., (1995) Gaudio, Marzo et al., 1991; Schwarz, Buchler, et al., 1996) .
We previously reported that patients who underwent partial (distal or proximal) gastrectomy and those with duodenal passage showed higher CD4/8 ratio levels concomitant with higher levels of CD4+ cells and lower levels of CD8+ cells after gastrectomy, and that these patients had better outcomes than did patients who underwent TG. Consequently, the former also had better outcomes than those of patients who underwent gastrectomy without duodenal passage reconstructions (Iwata, Ogoshi et al., 2001 ). We also previously reported that when tumors were located in the lower third of the stomach, patients who underwent DG showed better outcome than those who underwent TG or DFP reconstruction, especially when they received postoperative adjuvant therapies after gastrectomy (Nakamura, Ogoshi 2002) . In conclusion, gastric surgeons must exercise care in selecting among surgical resection procedures and postoperative adjuvant therapy when treating adenocarcinoma of middle gastric cancer.
